

ACS NLCRT Lung Cancer Biomarker Testing ECHO Year 3

Post Session 1: Recap & Resources

This document compiles some of the key resources mentioned during the **Session 1: Understanding the Barriers and Pathways to Biomarker Testing**. To review all publications, articles, or commentaries mentioned, we recommend reviewing the presentation recording and PowerPoint presentation.

All slides and recordings can be found [here](#).

CASE PRESENTATION SUMMARY & FEEDBACK

- Case Summary and Feedback [Link](#)

HIGHLIGHTS OF SESSION RESOURCES

Current State of Molecular Biomarker Testing:

- Liquid Biopsy for Advanced NSCLC: A Consensus Statement from the International Association for the Study of Lung Cancer [Link](#)
- Targeted Therapies for Lung Cancer Patients With Oncogenic Driver Molecular Alterations [Link](#)
- National Roundtable Stakeholder Confessionals [Link](#)
- National Lung Cancer Roundtable 2022 Biomarker Summit Executive Summary [Link](#)
- Race, Poverty, and Initial Implementation of Precision Medicine for Lung Cancer [Link](#)

Treatment & Survival Rate:

- Associations Among Optimal Lung Cancer Treatment, Clinical Outcomes, and Health Care Utilization in Patients Who Underwent Comprehensive Genomic Profiling [Link](#)
- Patients treatment-naive advanced ALK-Positive NSCLC in the ALEX study [Link](#)
- NSCLC patients treated with Pembrolizumab- Keynote-0001 Study [Link](#)
- Osimertinib in Resected EGFR-Mutated NSCLC- ADAURA trial [Link](#)

Practice Guidelines:

- Molecular testing guidelines for treatment with targeted Tyrosine Kinase Inhibitors [Link](#)
- IASLC Global Molecular Database for Thoracic Malignancies [Link](#)
- Genomic Profiling of Advanced NSCLC in Community Settings: Gaps and Opportunities [Link](#)

TOOLS/RESOURCES

- The Biomarker Testing Implementation Roadmap for Advanced Non-Small Cell Lung Cancer (NSCLC) by Association of Community Cancer Centers (ACCC) [Link](#)